Boswellia in Oncology Overview
What Boswellia is, how it relates to frankincense, and why AKBA matters in oncology
Boswellia refers to resin from species such as Boswellia serrata, B. sacra, and B. carterii. Many readers know it by the more familiar name frankincense. In oncology research, the main compounds of interest are the boswellic acids, especially AKBA (3-O-Acetyl-11-keto-β-boswellic acid), which is the most studied anticancer constituent.
At a Glance
What it is: A resin-derived triterpene extract from Boswellia, often known traditionally as frankincense
Main active focus in oncology: AKBA
Why it matters: It targets inflammation, survival signalling, angiogenesis, metastasis, treatment resistance, and brain-tumour-related oedema
Best-supported use today: Adjunctive use, especially around inflammatory burden, radiotherapy support, and neuro-oncology relevance
Main limitation: Oral bioavailability is near nil without encapsulation in Liposomes. Formulation standardisation also matters greatly.
Traditional use
Boswellia resin has been used for thousands of years in Ayurvedic, Middle Eastern, and North African traditions. It has long been used for inflammatory conditions, pain, wound support, and systemic illness.
Active constituents
Key boswellic acids include:
AKBA — 3-O-Acetyl-11-keto-β-boswellic acid
KBA — 11-keto-β-boswellic acid
ABA — 3-O-Acetyl-β-boswellic acid
α-BA and β-BA
In oncology, AKBA is the main compound of interest and should be treated as the most relevant standardisation marker.
Why Boswellia is studied in oncology
Boswellia attracted oncology interest because of its unusually strong anti-inflammatory activity. Research then expanded when investigators found that AKBA also influences apoptosis, NF-κB, PI3K/Akt, EGFR-related signalling, metastasis, angiogenesis, and treatment resistance.
It is especially notable in neuro-oncology, where Boswellia has clinical relevance for reducing radiation-induced cerebral oedema while also showing tumour-directed biological activity.
Clinical Positioning
Current evidence best supports Boswellia as an investigational adjunct rather than a standalone anticancer therapy.
Its strongest current practical roles are in the overlap between:
inflammation reduction
radiotherapy support
cerebral oedema management in brain tumour settings
multi-pathway adjunctive support
resistance-modifying strategies in selected preclinical models
Evidence Quality Rating
3.5/5 — Moderate-to-strong preclinical evidence with emerging clinical data
This rating reflects substantial mechanistic work, meaningful early human data, and unusually relevant clinical findings in glioblastoma-related oedema and early breast-cancer tissue response.
Boswellia deep dive, where to go next
Key References
Anti-cancer properties of boswellic acids: mechanism of action as an anti-cancerous agent https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1187181/full
The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC10959833/
An Update on Pharmacological Potential of Boswellic Acids in Cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC6747466/
Jump to another Boswellia page
Core pages
Mechanism deep dives
Practical pages
Cancer-type pages
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
Last updated
Was this helpful?